Gilead rated at outperform by RBC

RBC Capital Markets analyst Jason Kantor reiterated Gilead Sciences Inc. at outperform, average risk, after the company's acquisition of Myogen for $2.5 billion. The analyst raised the price target to $73 from $78. Upside beyond the price target could come if the HIV franchise delivers better-than-expected results or if darusentan phase 3 data is positive, according to Kantor. The company's broadened pipeline outside of HIV has increased its clinical, regulatory and execution risk. Shares of the Foster City, Calif.-based biopharmaceutical company were up $1.95, or 3.14%, at $63.98. (Nasdaq: GILD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.